Jefferies Group's INBX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 38,973 shares of Inhibrx Biosciences, Inc. (INBX) worth $2.62 M, representing 0.02% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Jefferies Group has initiated a new position in INBX, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 30,072 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Inhibrx Biosciences (INBX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Inhibrx Biosciences (INBX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +30,072 | Add 337.85% | 38,973 | $67.23 |
| Q4 2025 | +8,901 | New Buy | 8,901 | $79.00 |
Jefferies Group's Inhibrx Biosciences Investment FAQs
Jefferies Group first purchased Inhibrx Biosciences, Inc. (INBX) in Q4 2025, acquiring 8,901 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Inhibrx Biosciences, Inc. (INBX) for 2 quarters since Q4 2025.
Jefferies Group's largest addition to Inhibrx Biosciences, Inc. (INBX) was in Q1 2026, adding 38,973 shares worth $2.62 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 38,973 shares of Inhibrx Biosciences, Inc. (INBX), valued at approximately $2.62 M.
As of the Q1 2026 filing, Inhibrx Biosciences, Inc. (INBX) represents approximately 0.02% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Inhibrx Biosciences, Inc. (INBX) was 38,973 shares, as reported at the end of Q1 2026.